Newsroom

Sorted by: Latest

-

Rosen Law Firm Encourages Klarna Group plc Investors to Inquire About Securities Class Action Investigation – KLAR

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Klarna Group plc (NYSE: KLAR) resulting from allegations that Klarna may have issued materially misleading business information to the investing public. So What: If you purchased Klarna securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Ro...
-

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no tr...
-

TheOther Debuts Premium Matcha at an Intimate Art Basel Celebration in Miami Co-Hosted By Central Cee

MIAMI--(BUSINESS WIRE)--TheOther, a premium matcha brand sourcing ceremonial-grade, first harvest matcha from Uji, Japan, made its official debut during Art Basel with an intimate multi-sensory dinner last night at Forte Dei Marmi followed by a private after party at SOPRA Club in Miami Beach. Co-hosted by British Rapper Central Cee, the evening celebrated TheOther Master’s Blend, a first-harvest matcha crafted in collaboration with one of Japan’s most respected tea-growing lineages, spanning o...
-

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced interim data from its ongoing Phase 1/2 multidose study of VGA039 in von Willebrand disease (VWD). The data are being presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. VGA039 is a first-in-class monoc...
-

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (Abstract #265) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Both KITE-753 and...
-

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data are being presented during an oral presentation at the 67th American Society o...
-

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refractory multiple myeloma (RRMM) patients who had received at least three prior lines of therapy. These new...
-

Worthington Steel Issues Statement Regarding Klöckner & Co SE

COLUMBUS, Ohio--(BUSINESS WIRE)--Worthington Steel, Inc. (NYSE: WS) today issued the following statement: We confirm that we are in negotiations with Klöckner & Co SE about a potential voluntary public takeover offer of Klöckner & Co SE. No investment decision has been made now and the discussions may not result in a transaction. The Company does not intend to comment further. About Worthington Steel Worthington Steel (NYSE:WS) is a metals processor that partners with customers to deliv...
-

Lattice remporte le 2025 Global Semiconductor Alliance Award

HILLSBORO, Oregon--(BUSINESS WIRE)--Lattice Semiconductor (NASDAQ : LSCC), leader dans le domaine des semi-conducteurs programmables à faible consommation, a annoncé aujourd’hui avoir été sélectionnée comme « Entreprise publique la plus respectée dans le secteur des semi-conducteurs » lors des 2025 Global Semiconductor Alliance (GSA) Awards. Les GSA Awards récompensent les entreprises qui ont fait preuve d’excellence par leur succès, leur vision, leur stratégie et leurs opportunités futures dan...
-

Lattice ottiene il 2025 Global Semiconductor Alliance Award

HILLSBORO, Oregon--(BUSINESS WIRE)--Lattice Semiconductor (NASDAQ: LSCC), leader nel settore dei dispositivi programmabili a basso consumo di potenza, oggi ha annunciato di essere stata selezionata come “Società pubblica di dispositivi a semiconduttori più rispettata” in occasione dei 2025 Global Semiconductor Alliance (GSA) Award, che vengono conferiti alle imprese che hanno dimostrato eccellenza attraverso il successo conseguito, la visione, la strategia e le opportunità sfruttabili nel setto...